Galectin Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GALT research report →
About the company
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer.
- CEO
- Joel Lewis
- IPO
- 2002
- Employees
- 15
- HQ
- Norcross, GA, US
Price Chart
- Market Cap
- $297.01M
- P/E
- -11.08
- P/S
- 0.00
- P/B
- -2.28
- EV/EBITDA
- -22.48
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 21.05%
- ROIC
- -192.30%
- Revenue
- $0 · 0.00%
- Net Income
- $-30,836,000 · 34.46%
- EPS
- $-0.48 · 36.84%
- Op Income
- $-20,085,000
- FCF YoY
- 42.84%
- 52W High
- $7.13
- 52W Low
- $2.03
- 50D MA
- $2.72
- 200D MA
- $3.71
- Beta
- 0.49
- Avg Volume
- 586.11K
Get TickerSpark's AI analysis on GALT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 26, 26 | Shlevin Harold H. | other | 7,732 |
| Jun 29, 26 | Shlevin Harold H. | other | 22,268 |
| Jun 29, 26 | Shlevin Harold H. | other | 22,268 |
| Jun 26, 26 | Shlevin Harold H. | other | 7,732 |
| Jun 29, 26 | Shlevin Harold H. | sell | 22,268 |
| Jun 26, 26 | Shlevin Harold H. | sell | 7,732 |
| Jun 26, 26 | Jamil Khurram | other | 2,037 |
| Jun 29, 26 | Jamil Khurram | other | 47,467 |
| Jun 26, 26 | Jamil Khurram | other | 2,533 |
| Jun 26, 26 | Jamil Khurram | other | 2,533 |
Our GALT coverage
Recent articles, reports, and earnings notes.
No research on GALT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GALT report →Similar companies
Peers in the same neighborhood.